Sleep is a vital circadian process closely linked to immune system function, homeostatic mechanisms, psychological well-being, cognitive functioning, as well as quality of life in people. [1] [2] [3] [4] These functions of sleep are critical in the oncology population throughout the disease trajectory, to maximize health and well-being. 5, 6 The high incidence and psychophysiological morbidities of sleep disturbance in general cancer patients have been discussed in the literature, 5,7-11 highlighting its impact on quality of life 5,6 and the clinical consequences for patients and their caregivers, such as poorer treatment adherence and disease outcomes. 8, 12 Unfortunately, brain tumor (BT) populations have largely been overlooked in this research. Although there are several reviews of sleep disturbance and its management in the oncology population in general, 8, 13, 14 studies that assessed sleep disturbance in BT populations were rarely included in data synthesis, nor have they been considered previously within a specific systematic review. A high prevalence of sleep disturbance has been increasingly recognized in clinical practice. Evidence also suggests a unique pathophysiology of disrupted sleep-wake rhythms related to BT itself or BT-related treatments. 15, 16 Yet, understanding sleep disturbance and developing options for management have been neglected areas in both neuro-oncology care and research.
outcomes; (iii) current practice of sleep interventions; and (iv) association between patient and caregiver in the dyad's sleep.
Methods
This systematic review followed the established guidelines for systematic reviews and meta-analyses (the Preferred Reporting Items for Systematic Reviews and MetaAnalyses [PRISMA] statements). 17 
Search Strategy
The complete search method is outlined in Supplementary  Table S1 . A search of the scientific literature was conducted on 7 electronic databases (eg, PubMed, Embase) for published articles. In the gray literature, dissertations, theses, and conference proceedings and abstracts were searched to circumvent the possible influence of publication bias on review results. Search terms used were keywords or Medical Subject Headings terms related to sleep, cranial cancer, and sleep-targeted intervention, spreading the search to their related or stemmed words. Initial searches using a combination of all 3 search terms yielded a smaller number of reports, compared with the search results using sleep and cancer terms only. Therefore, a combination of sleep and cancer terms was used in searches. Searches were limited to human studies published in English between January 1990 and September 2015. Additional manual searches identified potentially eligible studies from reviews or meta-analyses and from the reference lists of relevant studies. Paper copies of the journal for which full text was not available electronically were searched.
Study Selection
The authors independently reviewed the potential relevance of all titles and abstracts identified from the searches and then full-text copies of all articles judged potentially relevant from the initial screening based on the eligibility criteria for inclusion. Inclusion criteria were: (i) adults (≥18 y) with a primary (malignant, nonmalignant) or secondary (metastatic) BT and their adult family caregivers; (ii) empirical study report or case report; and (iii) reporting sleep outcomes using one of the following measures:
• validated self-report sleep assessments • validated health-related quality of life (HRQoL) scales with ≥1 sleep item • validated psychological (eg, mood) assessments with ≥1 sleep item • validated symptom assessments with ≥1 sleep item • sleep log or diary kept for ≥3 consecutive sleep-wake cycles • actigraphy (ACT), polysomnography (PSG), or sleep electroencephalogram (EEG) Exclusion criteria were: (i) reviews, book chapters, or opinions; (ii) no sleep outcome reported; (iii) use of nonvalidated sleep assessment; (iv) adult survivors of pediatric brain cancer or caregivers of a child with BT; (v) unable to distinguish BT sleep data from mixed cancer samples; and (vi) duplicate reports of identical results.
Data Extraction and Quality Assessment
Data were extracted for the study objective, design, sample size, demographic and clinical characteristics of the study population, intervention (or exposure), sleep assessment tool, and outcomes related to sleep. Data extraction was aided by using a data extraction template and NVivo qualitative data analysis software (QSR International v11 Pro, 2015). All included studies were assessed against each of the questions in a quality assessment checklist (see Supplementary  Table S2 ) and subsequently given an overall quality rating of poor, fair, good, or cannot determine. The overall quality rating of 10 of 50 studies was conducted independently by 2 authors (M.J. and M.A.) and the results compared. As the ratings agreed for all 10 studies, quality assessments for the rest of the included studies were conducted by one author (M.J.). All 3 authors confirmed the quality rating results and discussed and came to consensus on the final quality rating results. Only the studies of fair or good quality were included in the data synthesis to answer the review questions.
Data Synthesis
Studies were categorized as (i) sleep intervention study, (ii) descriptive sleep study, or (iii) descriptive HRQoL study, according to the main focus or objective of each study for this review. A study which aimed to assess an intervention intended to bring about a change in the sleep-related symptoms or interference was referred to as a sleep intervention study. A study, without a sleep-specific intervention, which described the participants in terms of sleep or sleep within HRQoL was referred to as a descriptive sleep study or a descriptive HRQoL study, respectively. Any systematic difference between study groups, or pre/posttreatment, within a specific descriptive study was noted as an exposure variable and its effect on sleep outcomes was reviewed if applicable. In order to review the prevalence and severity of sleep disturbance, the cutoff score of a number of standardized, multi-item sleep assessments was used, namely the Pittsburgh Insomnia Quality Index (PSQI), 18 the Insomnia Severity Index (ISI), 19 and the Epworth Sleepiness Scale (ESS). 20 These self-reported outcome measures assess different facets of sleep disturbance, are not single-item or subscales of multisymptom HRQoL assessments, and have demonstrated psychometric properties and clinical utility for implying the clinically significant impairment. The physiological measures of sleep, such as ACT and PSG, were reviewed to determine the presence of impairments in sleep quantity, circadian rhythms, or sleep-related breathing.
Results
Electronic database searches identified a total of 1002 records for published articles and 37 records for the gray NeuroOncology literature. After the initial screening, 89 articles remained for full-text review, of which 48 articles were excluded as they did not meet eligibility criteria (43 articles), were duplicate reports of the same study results (3 articles), or were unobtainable as full texts (2 dissertations). An additional 32 articles were identified by the manual search, of which 9 were included after full-text assessment. Therefore, a total of 50 articles were included in this review (Figure 1 ).
Description of Studies
All 50 included studies were published in the form of journal articles. Publication years ranged between 1997 and 2015, with a noticeable increase in the number of studies reporting sleep and HRQoL outcomes of BT populations in the past 5 years (29 studies). Studies were spread globally, with most conducted in Europe and North America (43 studies) and some in Asia (7 studies).
All studies included were categorized into either descriptive sleep studies (n = 13) or descriptive HRQoL studies (n = 37). None of the studies could be categorized as a sleep intervention. Of 13 descriptive sleep studies, 4 examined sleep disturbance in mixed glioma patients, and 8 in benign BT such as pituitary adenoma or craniopharyngioma (Table 1 summarizes findings) . One study examined sleep characteristics of family caregivers of patients with primary malignant BT. 21 Several standardized HRQoL assessments developed for cancer populations include a sleep subscale. Of the 37 HRQoL studies, 17 used the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30), Brain Neoplasm module (QLQ-BN20), and a shorter version of the core questionnaire for palliative care (C15-PAL). Five studies used the MD Anderson Symptom Inventory-Brain Tumor module (MDASI-BT). In both HRQoL tools, sleep disturbance (also called insomnia) and drowsiness were important facets of the BT patients' HRQoL, [22] [23] [24] although only assessed by a single question.
The quality assessment rated 10 studies as good and 36 as fair. Four studies were rated as poor in quality and were excluded from the synthesis of findings (3 HRQoL and 1 sleep study; see Supplementary Table S3) . 
NeuroOncology
Type, Prevalence, Severity, and Potential
Contributing Factors of Sleep Disturbance in Patients with Brain Tumor

Types of sleep disturbance
A wide variety of sleep-related terms were used across the studies, often interchangeably, to describe sleep disturbance. Sleep terms were not defined but included in the HRQoL assessments. The terms were largely integrated into 5 types of sleep disturbance (see Supplementary Table  S4 for sleep-related terms identified under each type): (i) dissatisfaction with sleep quality; (ii) nonspecific disturbed sleep; (iii) insomnia symptoms (disruption in sleep quantity, pattern, or architecture); (iv) sleep apnea; and (v) somnolence. Nonspecific disturbed sleep and somnolence were the most frequently reported sleep complaints, Abbreviations: NFMA, nonfunctioning macroadenoma; VAS, visual analogue scale; REM, rapid eye movement; RT, radiotherapy; PRO, patient reported outcome; GBM, glioblastoma; LGG, low grade glioma; AA, anaplastic astrocytoma; BMI, body mass index. 
Prevalence and severity of sleep disturbance using the PSQI, ISI, and ESS
The prevalence and severity of sleep disturbance were reviewed from studies that used standardized, multiconstruct sleep assessments: PSQI, ISI, and ESS. Mean scores of these measures and percentages of the sample whose scores were above the clinical thresholds are shown in Table 2 . PSQI global score greater than 5 is indicative of significant sleep disturbance. 18 Mean PSQI global scores in brain tumor samples were to some extent above the cutoff in all 4 studies [25] [26] [27] [28] and were significantly higher than the controls in 2 studies of benign BT patients. 26, 27 None of the studies computed the percentage of the sample above the cutoff. Given seemingly large variations in the scores, it was difficult to determine the prevalence and severity based on the PSQI. The ESS assesses daytime somnolence, and scores above 10 indicate severe somnolence that would require clinical interventions. 20, 29 Baseline mean scores varied between the studies ranging from 5.9 to 10.3, also with large standard deviations. The prevalence rates of clinically impaired somnolence ranged between 21% and 29% in 5 studies. 25, [30] [31] [32] [33] One study assessed insomnia in pineocytoma and low-grade BTs using the ISI. Low-grade tumor patients who underwent craniotomy reported a greater level of insomnia than pineocytoma and non-BT control groups. 26 
Prevalence and severity of sleep disturbance reported in the HRQoL studies
Sleep disturbance and/or drowsiness were repeatedly reported as one of the most prevalent and severe symptoms, along with fatigue and psychological distress in many of the HRQoL studies involving malignant or metastatic BT samples. [34] [35] [36] [37] [38] [39] [40] [41] Mean scores of insomnia and drowsiness scales of the EORTC QLQs of the included studies are shown in Table 3 . Mean scores of sleep symptom items of the MDASI-BT are similarly shown in Table 4 . The severity of sleep disturbance items were similarly rated among the studies, despite wide variation in BT patients. Moderate to severe symptom distress was seen in 27%-34% for sleep disturbance and in 22%-32% for drowsiness. [34] [35] [36] These sleep symptoms were often ranked the first or second most severe symptom reported with fatigue. 34, [37] [38] [39] Fatigue appeared to be the most frequent complaint among brain tumor patients, and there was a significant association between fatigue and sleep disturbance. 32, 39, 41, 42 No further comparison or statistical analysis was possible given the heterogeneity in the samples.
Clinical associations with sleep disturbance
Tumor Characteristics. This review included studies of heterogeneous groups of the brain tumor population LG, low grade; NFPA, nonfunctioning pituitary adenoma; GBM, glioblastoma. * Significant difference (P < .05) from the control group within the study. ESS scores were transformed to scores 0-100, 0 being the worst somnolence. The cutoff of ≤50 was used for computing % of clinically impaired somnolence. 
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LGG, low grade glioma; AA, anaplastic astrocytoma; GBM, glioblastoma; RT, radiotherapy; TMZ, temozolomide; PCB, procarbazine. Some studies explored whether BT location and laterality had a particular association with sleep regulation or related HRQoL. Patients with PBT have diverse clinical manifestations and impairments due to variability in underlying neurobiology, locations, and treatment regimens. 32, 44 For instance, tumors located near the neural substrates that regulate sleep-wake rhythms and hormonal secretions may disrupt the patient's sleep patterns or quality. However, such an effect of tumor laterality or location on sleep or the HRQoL outcomes was not found in PBT patients. 43, [45] [46] [47] Two studies conducted in patients with PBTs in Finland reported that poorer sleep was described by patients with anterior than posterior 47 and bilateral than unilateral tumors. 45 However, such location or laterality effects on sleep were mediated by restlessness or depression. 45, 47 There was no difference in sleep between tumor histology groups. 47 Surgery. Cranial surgery was the initial treatment for brain tumors in almost all participants. Three studies specifically examined sleep and HRQoL before and after surgery 45, 46 or different surgery types, 26 and 2 studies examined pre-surgery states of sleep and HRQoL. 43, 48 Patients who underwent craniotomy showed poorer sleep quality and more sleep disturbance than the matched control patients who received lumbar discectomy, showing a negative impact of surgery in the brain. 26 In contrast, sleep disturbance improved significantly at 3 months and 1 year following the tumor resection surgery in within-subject comparisons. 45 However, the PSG conducted in a sample of 11 mixed glioma patients showed no changes in sleep quantity or patterns before and after the surgery. 46 Nevertheless, sleep disturbance and drowsiness were highly prevalent in PBT patients prior to surgery, as assessed by the QLQ-C30 and QLQ-BN20. 43, 48 Other studies had patients with different surgical treatment profiles, and it was unclear whether previous surgery had any relationship with reported sleep disturbance.
Radiotherapy. An interesting pattern of somnolence was seen in PBT patients following cranial irradiation treatment. In a cohort of 19 PBT patients (79% high-grade gliomas [HGGs]), 16 developed mild to severe somnolence. 16 Somnolence had a distinct trajectory consisting of 2 phases. Its onset was seen at 2 weeks post-irradiation, reaching a peak over the next week, then it resolved. The symptom reappeared at 5 weeks post-irradiation lasting 2-5 days. This cyclic pattern of somnolence was similarly shown in a larger cohort of 68 PBT patients, with greater somnolence from 3 weeks and peaking at 6-12 weeks postirradiation before resolving. 49 Both studies were conducted by the same research group, and it is unknown whether this pattern can be replicated in other centers.
The effects of whole brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) on sleep disturbance and drowsiness were studied in cohorts of MBT patients. Drowsiness was prevalent in MBT patients before and after WBRT. 42, 50 In a slightly older cohort, significantly more drowsiness was reported at 12 weeks posttreatment than baseline. 42 Studies assessing 2 different types of SRS in MBT patients had either a small sample size 51 or short survival times. 52 Consequently, groups in 2 SRS arms were combined for analysis, and it was not possible to draw a conclusion about their effects on sleep.
Radiotherapy with Concurrent Chemotherapy. Radiotherapy with concurrent chemotherapy was a widely used treatment option for HGG patients. In a cohort of elderly glioblastoma patients (n = 65; age range, 70-81 y), changes in HRQoL, including sleep disturbance and drowsiness, were assessed pre-and postradiotherapy with concurrent chemotherapy. 53 While mean scores were unchanged for sleep disturbance, worse drowsiness was reported at a 6-month follow-up. Sleep disturbance improved in 29% for 6 months after treatment. Similar improvements in sleep disturbance and drowsiness were seen in a different cohort of GBM patients at different time points following treatment. However, improvements in sleep symptoms did not persist. 54 An international cohort of 544 glioblastoma patients treated with either radiotherapy alone (control) or concurrent radiotherapy and chemotherapy had their HRQoL assessed using the EORTC QLQs. 55 While the 2 groups did not differ on any of the HRQoL scales, including sleep and drowsiness at baseline, overall HRQoL was impaired in both groups. The most substantial impairments were seen in fatigue and sleep disturbance in glioblastoma patients. During treatment and follow-up assessments, there was no group difference in HRQoL. Patients in both treatment arms showed a trend to improved HRQoL that was not statistically significant. 55 Chemotherapy. One study 56 compared the effects of 2 chemotherapy agents, temozolomide and procarbazine, on HRQoL outcomes of recurrent glioblastoma patients recruited for 3 different trials. Sleep disturbance scores (insomnia from QLQ-C30) did not change from baseline in patients receiving temozolomide regardless of tumor progression. However, drowsiness became worse in those patients who had tumor progression but improved in those without progression. Patients receiving procarbazine reported greater decline in HRQoL, including drowsiness, compared with temozolomide. Regardless of tumor progression, most HRQoL scores became worse in patients in the procarbazine trial. Although temozolomide had more favorable results than procarbazine in this study, more evidence is needed to determine the effects of temozolomide on sleep symptoms in BT patients.
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Corticosteroids. The use of corticosteroids in BT patients may disrupt patients' sleep. 57 Dexamethasone use during radiotherapy was reported in a number of studies, but none found or reported significant effects of dexamethasone on sleep. 32, 42, 55, 58, 59 One study examined the associations between dexamethasone use and HRQoL in a cohort of MBT patients (n = 68) undergoing WBRT. 60 Patients received a mean dose of 13.8 mg/day (range = 0.5-32) dexamethasone and concurrent palliative WBRT. Sleep was assessed by using 2 single-item sleep scales of HRQoL. They found that patients on a higher dose than 16 mg/day had a more disturbed sleep at week 2 during the treatment. But no other significant changes in sleep related to dexamethasone dose or duration were observed over time. Only a small number of patients remained at high doses of dexamethasone after week 2, rendering further interpretation difficult.
Physiological Assessments and Patient-Reported Outcomes of Sleep Disturbance
This review also aimed to address whether, and to what extent, objective and subjective assessments of sleep in BT patients agree with each other. A total of 6 studies used an objective assessment of sleep, 5 had patients with a benign BT involving the pituitary region. Among these 5 studies, 2 were case reports of 2 male patients with different subtypes of pituitary adenoma. They reported rare clinical presentations of narcolepsy developed post-irradiation 61 or circadian rhythm sleep disorders which led to diagnosis of the pituitary tumor. 62 The cases differed greatly in both demographic and clinical characteristics. In both cases, the PSG or ACT outcomes were used diagnostically and not compared with patient-reported outcomes.
The other 3 studies reported objective sleep outcomes obtained by PSG and/or ACT, as well as patient-reported outcomes using the PSQI, ESS, or sleep diary. These studies drew comparisons with matched control groups. There was no clear pattern of sleep disturbance among the objective data or between objective and subjective outcomes, even within the same study. For example, sleep of 17 nonfunctioning macroadenoma patients in long-term remission was assessed using the PSG, ACT, and sleep questionnaires. 25 They found that while PSG data showed normal duration of sleep and latency but poorer sleep efficiency of patients compared with controls, ACT data showed increased time spent in bed and sleeping, and a normal level of sleep efficiency in patients. However, patients self-reported having to wake more often during the night and suffering from more sleep disturbance than controls.
One study using PSG in a small cohort of glioma and meningioma patients (n = 11) focused on sleep-related breathing patterns and changes before and after tumor resection. 46 Clinically significant sleep apnea was detected in 7 patients. Sleep parameters were mostly unchanged post-operation, while sleep-related breathing improved in all patients. Although reduced mean sleep time (<5 h) overall and an increased rapid eye movement sleep percentage after resection was shown, no discussion of other sleep parameters was attempted. There was a lack of evidence of objectively assessed sleep outcomes, particularly in patients with malignant PBT or MBT, to answer the review question.
Sleep Intervention Targeted at Brain Tumor Patients and Caregivers
We failed to identify evidence of the development or examination of any interventions for managing sleep symptoms of BT patients and caregivers. However, a couple of studies briefly reported the use of sleep interventions. A case report revealed that oral melatonin was administered for 3 months (5-10 mg/day at 21:30 or 23:00 h) to improve irregular sleep-wake patterns of a pituitary microadenoma patient in Israel; however, no detailed outcomes were reported. 62 Oral melatonin was stopped after 3 months due to ineffectiveness. Another study described a trial of treatment with continuous positive air pressure therapy or modafinil in craniopharyngioma patients with diagnoses of sleep apnea or somnolence, with effectiveness reported on an individual basis without formal sleep assessment (n = 13). 31 
Sleep Disturbance of Patients and Caregivers
The final review question asked how, and to what extent, sleep disturbance of patients and caregivers would be comparable and affect each other. Only one study 21 examined sleep characteristics of 133 adult family caregivers within 1 or 2 months following the patients' diagnosis of malignant PBT. Caregivers' sleep was assessed using a wrist accelerometer (ACT) and the sleep quality subscale of the PSQI. In comparison to the parameters of healthy sleep for adults (ie, sleep duration of 7 hours for restoration, with a sleep onset <15 minutes after lying down, and <10% wake time during the nocturnal sleep period [the American Academy of Sleep Medicine]), the caregivers took significantly longer time (mean ± SD = 35 ± 34.5 min, P < .01) to fall asleep, and slept for less time (mean ± SD = 5 h 57 min ± 84.6 min, P < .01) than recommended. Caregivers had frequent awakenings during sleep (wake after sleep onset = 15.1%, P value not reported), and 48% of caregivers required a nap during the daytime. Poor sleep quality was reported by 32% (n = 42) of the caregivers. Significant associations were found between caregivers' sleep disturbance and their level of anxiety and the functional status (KPS) of the patient. The patient's tumor type or patientcaregiver relationship type was not associated with the caregiver's sleep. Unfortunately, it was not possible to compare the patient and caregiver sleep disturbances and their influence on each other's sleep, as no sleep outcomes were reported for the patients.
Discussion
The primary objective of this review was to gather evidence to identify types of sleep disturbance that are prevalent in adult brain tumor patients and report the level of severity. To our knowledge, this is the first systematic review to synthesize all evidence available from a broad range of nonpediatric brain tumor groups, from benign, to malignant, to metastatic BTs, captured by all measures of sleep disturbance. The majority of studies reviewed (41 of 50) were published in the last decade, suggesting recent growing awareness of sleep-related complications in BT patients and the clinical importance of their impact on quality of life. 43, 63 Certain brain tumors are incurable and require ongoing treatments during the course of the illness. Toxicity or side effects of cancer treatment can cause a considerable amount of symptom distress in BT patients. 40 The use of patient-centered HRQoL assessments as an endpoint in clinical trials or palliative care settings is essential, as the potential impact on quality of life becomes increasingly important when choosing the optimal treatment. 55, 63 This review demonstrated that sleep is an important element of HRQoL in patients with BT, and it is commonly disturbed. A high prevalence and severity of sleep disturbance and drowsiness in BT patients, along with fatigue, were indicated by the results of many HRQoL studies included in this review. This finding is consistent with the findings of a review of HRQoL in patients with PBTs and MBTs. 64 The authors performed a data synthesis of 14 studies to compute average scores of the EORTC QLQ-C30 and QLQ-BN20 scales using the total number of participants in each study as the weighted variable in an analysis of variance. 64 The mean (SD) insomnia (ie, disturbed sleep) scores of the QLQ-C30 were 22.16 (65.07) and 37.49 (28.40) , which were the third and second highest symptom scores after fatigue, in PBT (n = 602) and MBT (n = 154), respectively. 64 Similarly, the mean (SD) drowsiness scores of the QLQ-BN20 were 24.83 (86.98) and 34.21 (34.08), which were the third and second highest symptom scores after future uncertainty, in PBT (n = 1579) and MBT (n = 154), respectively. 64 There are several limitations in the studies included in this review. Studies used a variety of measures in heterogeneous samples with many different clinical and treatment features. It was difficult to identify prevalent types, or clear clinical associations, of sleep disturbance because the results largely depended on an assessment of specific type of sleep disturbance in each study. Sleep outcomes were frequently reported as part of HRQoL outcomes of clinical trials, but as secondary and optional endpoints, and in an observational manner. The use of a single-item sleep scale within an HRQoL measure was common. Group differences in treatment arms on the sleep outcome were not usually reported. In addition, many studies suffered from the lack of statistical power due to small sample sizes or high attrition rates in longitudinal designs. This rendered study groups with a different exposure or clinical variable of interest to be later combined, and often only descriptive data were reported. This issue is particularly critical for research involving HGGs or brain metastases, which will have poor prognosis and rapid decline in physical and cognitive functioning. Caution is required when interpreting the results, as patients with higher functional status (KPS) and better prognosis tended to remain in the study longer for follow-up assessments. Patients with glioblastoma in one trial tended to drop out at the time of disease progression. 54 Compliant patients with HGG were more likely to have longer survival than noncompliant patients. 55 As a result, poorer performing patients may have been underrepresented, and overall performance of the population on HRQoL domains may be overestimated.
Evidence from comprehensive sleep-focused studies is scarce, particularly in patients with a malignant PBT or MBT. Formal sleep assessments were mostly conducted in small samples of benign tumors around the pituitary gland region. This part of the brain may be of interest given its neurophysiological involvement in the regulation of sleep. However, it will be difficult to exploit such data in drawing clinical implications for sleep management of patients with malignant brain tumors. In these studies, patients were in a long-term remission with nonfunctioning tumors or had their tumors surgically removed. These tumors lack clinical features of malignant tumors that may affect sleep. In fact, gliomas are the most common primary CNS cancer in adults, 65 75% of which are HGG. 66 Glioblastoma itself comprises 46% of all malignant PBTs in the US. 66 Also, brain metastases are common from lung or breast cancers. 42 The fact that HGG and MBT generally carry a poor prognosis and low functional status will hinder the use of overnight PSG assessment in a sleep laboratory. The use of standardized, multifaceted patient-reported sleep outcome assessments in these patients will be of value for research, as well as for potential use in routine cancer care.
There was no study which examined an intervention specifically targeted at improving the sleep of BT patients and/ or their caregivers. It is not surprising considering that little research has been done to determine the nature, prevalence, and etiology of sleep disturbance in neuro-oncology populations. We cannot rule out the possibility of effectiveness and successful implementation of sleep interventions in BT populations that have been used in the general or other cancer populations (see a review 67 of treatment options of insomnia in cancer). However, it is important to build a strong evidence base for the development of a suitable and effective intervention or management program tailored to patients with a brain tumor and their caregivers.
In conclusion, this systematic review highlights an emerging picture from studies reporting HRQoL outcomes that sleep disturbance is a highly prevalent and severe symptom causing distress in patients with brain tumor. Much of the available evidence is limited to describing the presence of sleep disturbance as part of overall performance status of patients across different treatment trajectories. There is a lack of research establishing a comprehensive understanding of the patterns, prevalence, severity, and risk factors of sleep disturbance in patients with malignant brain tumor and their caregivers and little assessing associations in the patient-caregiver sleep experience. Future research is warranted to perform a more systematic examination of sleep disturbance using standardized, multifaceted sleep assessments to inform the development of better symptom management programs in this population.
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